• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在肿瘤学中引出对替代药物疗法的偏好:治疗结果描述、引出技术和治疗经验对偏好的影响。

Eliciting preferences for alternative drug therapies in oncology: influence of treatment outcome description, elicitation technique and treatment experience on preferences.

作者信息

O'Connor A M, Boyd N F, Warde P, Stolbach L, Till J E

出版信息

J Chronic Dis. 1987;40(8):811-8. doi: 10.1016/0021-9681(87)90133-0.

DOI:10.1016/0021-9681(87)90133-0
PMID:3597681
Abstract

Several methodologic issues arise in eliciting preferences for therapy. Examples are the selection of appropriate descriptions of treatment outcomes and of elicitation techniques. Of particular importance is the correspondence of patients' anticipated preferences for treatment to actual preferences once they have experienced treatment. Treatment outcome descriptions and elicitation techniques were compared for a hypothetical drug decision problem involving trade-offs between quality and quantity of life. Preferences of 54 cancer patients were elicited before, and 6 weeks following initiation of chemotherapy treatment. Patients' preferences were not influenced by the way information about side effects was presented, nor the stated probability of survival at high and moderate levels. A riskless rating technique produced different preferences from those of a risky treatment choice method. Although patients experienced significant toxicity following initiation of treatment, their preferences remained stable on retest. The results raise questions about the extent to which patients are willing, at the time of decision making, to trade off survival rate for improved quality of life.

摘要

在引出对治疗的偏好时会出现几个方法学问题。例如,选择适当的治疗结果描述和引出技术。特别重要的是患者在经历治疗后,其预期的治疗偏好与实际偏好的对应关系。针对一个涉及生活质量和数量权衡的假设性药物决策问题,比较了治疗结果描述和引出技术。在化疗治疗开始前和开始后6周,引出了54名癌症患者的偏好。患者的偏好不受副作用信息呈现方式的影响,也不受高和中等水平生存概率陈述的影响。一种无风险评级技术产生的偏好与风险治疗选择方法不同。尽管患者在开始治疗后经历了显著的毒性,但他们在重新测试时的偏好保持稳定。结果引发了关于患者在决策时愿意在多大程度上用生存率换取生活质量改善的问题。

相似文献

1
Eliciting preferences for alternative drug therapies in oncology: influence of treatment outcome description, elicitation technique and treatment experience on preferences.在肿瘤学中引出对替代药物疗法的偏好:治疗结果描述、引出技术和治疗经验对偏好的影响。
J Chronic Dis. 1987;40(8):811-8. doi: 10.1016/0021-9681(87)90133-0.
2
Methodologic evaluation of adaptive conjoint analysis to assess patient preferences: an application in oncology.适应性联合分析评估患者偏好的方法学评价:在肿瘤学中的应用。
Health Expect. 2010 Dec;13(4):392-405. doi: 10.1111/j.1369-7625.2010.00595.x.
3
Eliciting preferences for alternative cancer drug treatments. The influence of framing, medium, and rater variables.
Med Decis Making. 1985 Winter;5(4):453-63. doi: 10.1177/0272989X8500500408.
4
Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices.以患者为中心的决策:运用联合分析确定偏好敏感型治疗选择的风险效益权衡。
J Neurol Sci. 2014 Sep 15;344(1-2):80-7. doi: 10.1016/j.jns.2014.06.030. Epub 2014 Jun 23.
5
Palliative chemotherapy preferences and factors that influence patient choice in incurable advanced cancer.姑息性化疗的偏好以及影响晚期不治之症患者选择的因素。
Jpn J Clin Oncol. 2008 Jan;38(1):64-70. doi: 10.1093/jjco/hym147. Epub 2008 Jan 31.
6
How decisions are reached: physician and patient.决策是如何达成的:医生与患者。
Ann Intern Med. 1982 Aug;97(2):262-8. doi: 10.7326/0003-4819-97-2-262.
7
Relationship between cancer patients' predictions of prognosis and their treatment preferences.癌症患者对预后的预测与其治疗偏好之间的关系。
JAMA. 1998 Jun 3;279(21):1709-14. doi: 10.1001/jama.279.21.1709.
8
Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making.参加I期试验的晚期癌症患者的补充和替代医学:一项关于预后、生活质量及决策偏好的研究。
J Clin Oncol. 2007 Feb 10;25(5):548-54. doi: 10.1200/JCO.2005.03.9800.
9
Effects of framing and level of probability on patients' preferences for cancer chemotherapy.
J Clin Epidemiol. 1989;42(2):119-26. doi: 10.1016/0895-4356(89)90085-1.
10
Desire for information and involvement in treatment decisions: elderly cancer patients' preferences and their physicians' perceptions.对信息的需求及参与治疗决策的情况:老年癌症患者的偏好及其医生的认知
J Clin Oncol. 2007 Nov 20;25(33):5275-80. doi: 10.1200/JCO.2007.11.1922.

引用本文的文献

1
Hernia Recurrence Risk Matters More Than Mesh Type to Patients Undergoing Ventral Hernia Repair.对于接受腹疝修补术的患者而言,疝复发风险比补片类型更为重要。
J Surg Res. 2025 Jul;311:212-220. doi: 10.1016/j.jss.2025.04.028. Epub 2025 May 28.
2
fMRI evidence of a hot-cold empathy gap in hypothetical and real aversive choices.假设和真实厌恶选择中热冷共情差距的 fMRI 证据。
Front Neurosci. 2013 Jun 10;7:104. doi: 10.3389/fnins.2013.00104. eCollection 2013.
3
Are patients' judgments of health status really different from the general population?
患者对健康状况的判断真的与一般人群不同吗?
Health Qual Life Outcomes. 2011 May 11;9:31. doi: 10.1186/1477-7525-9-31.
4
Decision making and quality of life in the treatment of cancer: a review.癌症治疗中的决策制定与生活质量:综述
Support Care Cancer. 2009 Feb;17(2):117-27. doi: 10.1007/s00520-008-0505-2. Epub 2008 Sep 19.
5
Barriers to obtaining diagnostic testing for coronary artery disease among veterans.退伍军人中获得冠状动脉疾病诊断检测的障碍。
Am J Public Health. 2008 Dec;98(12):2207-13. doi: 10.2105/AJPH.2007.123224. Epub 2008 Apr 1.
6
A typology of preferences for participation in healthcare decision making.参与医疗保健决策的偏好类型学。
Soc Sci Med. 2006 Sep;63(5):1158-69. doi: 10.1016/j.socscimed.2006.03.030. Epub 2006 May 11.
7
The effect of age, race and gender on preference scores for hypothetical health states.年龄、种族和性别对假设健康状态偏好分数的影响。
Qual Life Res. 2006 May;15(4):645-53. doi: 10.1007/s11136-005-3514-3.
8
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer.权衡量化:绝经后淋巴结阴性乳腺癌患者化疗随机试验中的生活质量和质量调整生存期
Br J Cancer. 2004 Nov 29;91(11):1893-901. doi: 10.1038/sj.bjc.6602230.
9
Stability of time trade-off utilities for health states associated with the treatment of prostate cancer.与前列腺癌治疗相关健康状态的时间权衡效用的稳定性。
Qual Life Res. 2002 Aug;11(5):405-14. doi: 10.1023/a:1015609126536.
10
Development of a preference-weighted health status classification system in France: the Health Utilities Index 3.法国偏好加权健康状况分类系统的开发:健康效用指数3
Health Care Manag Sci. 2002 Feb;5(1):41-51. doi: 10.1023/a:1013201102918.